MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-07-2025
Canopy Growth Corporation EV - Enterprise Value 2011-2025 | CGC
Annual EV - Enterprise Value Canopy Growth Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 459 M | 1.27 B | 1.04 B | 828 M | 5.29 B | 5.57 T | 1.26 K | 4.16 B | 793 M | 158 M | 53.1 M | - | - | - | - |
All numbers in CAD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 5.57 T | 1.26 K | 507 B |
EV - Enterprise Value of other stocks in the Drug manufacturers industry
| Issuer | EV - Enterprise Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Alimera Sciences
ALIM
|
197 M | - | - | $ 142 M |  USA |
 |
Assertio Holdings
ASRT
|
141 M | $ 0.74 | -3.53 % | $ 52.6 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
737 M | - | - | $ 754 M | USA |
 |
AcelRx Pharmaceuticals
ACRX
|
23.6 M | - | 7.5 % | $ 6.35 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
28.5 M | - | 0.86 % | $ 117 M | USA |
 |
Cronos Group
CRON
|
3.84 B | $ 3.03 | -7.49 % | $ 1.61 B |  Canada |
 |
Agile Therapeutics
AGRX
|
25.3 M | - | 10.11 % | $ 58.2 M | USA |
 |
Aurora Cannabis
ACB
|
106 M | $ 5.12 | -5.19 % | $ 86.3 M | Canada |
 |
Catalent
CTLT
|
16.7 B | - | - | $ 11.5 B | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
10.2 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
284 M | - | 2.45 % | $ 38.1 M | Canada |
 |
DURECT Corporation
DRRX
|
3.37 M | - | - | $ 50.1 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
457 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
-710 M | - | - | $ 28.9 M |  Irlanda |
 |
Emergent BioSolutions
EBS
|
1.2 B | $ 12.12 | 6.13 % | $ 621 M | USA |
 |
Evoke Pharma
EVOK
|
7.15 M | $ 10.96 | 0.09 % | $ 36.6 M | USA |
 |
Athenex
ATNX
|
209 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
756 M | $ 21.4 | 0.16 % | $ 2.04 B |  France |
 |
Evolus
EOLS
|
1.03 B | $ 7.16 | 1.7 % | $ 444 M | USA |
 |
Harrow Health
HROW
|
515 M | $ 46.04 | -2.17 % | $ 1.5 B | USA |
 |
China Pharma Holdings
CPHI
|
11.1 M | $ 1.55 | -0.26 % | $ 27.1 M |  China |
 |
Bausch Health Companies
BHC
|
29.9 B | $ 6.86 | -0.87 % | $ 2.5 B | Canada |
 |
Lannett Company
LCI
|
648 M | - | 1.15 % | $ 7.11 M | USA |
 |
Organogenesis Holdings
ORGO
|
392 M | $ 4.78 | -0.93 % | $ 629 M | USA |
 |
OrganiGram Holdings
OGI
|
456 M | $ 1.78 | -7.55 % | $ 402 M | Canada |
 |
Pacira BioSciences
PCRX
|
1.68 B | $ 26.49 | 0.76 % | $ 1.23 B | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
124 M | $ 3.02 | 19.37 % | $ 42.5 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
-110 M | - | - | $ 193 M | Canada |
 |
Rockwell Medical
RMTI
|
57.3 M | $ 0.88 | -5.2 % | $ 20.5 M | USA |
 |
Solid Biosciences
SLDB
|
197 M | $ 5.8 | -1.28 % | $ 237 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
7.57 M | $ 3.51 | -2.11 % | $ 4.36 M | USA |
 |
PetIQ
PETQ
|
280 M | - | 1.64 % | $ 400 M | USA |
 |
Relmada Therapeutics
RLMD
|
170 M | $ 4.34 | 6.9 % | $ 131 M | USA |
 |
Jupiter Wellness
JUPW
|
91.9 M | - | - | $ 33.6 M | USA |
 |
Perrigo Company plc
PRGO
|
8.73 B | $ 12.83 | -2.36 % | $ 1.76 B | USA |
 |
ProPhase Labs
PRPH
|
145 M | $ 0.11 | -2.7 % | $ 1.74 M | USA |
 |
Radius Health
RDUS
|
700 M | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
220 M | - | -4.76 % | $ 65.3 M | USA |
 |
Veru
VERU
|
111 M | $ 2.44 | 0.83 % | $ 329 M | USA |
 |
Sundial Growers
SNDL
|
-2.47 M | $ 1.94 | -12.22 % | $ 3.37 M | Canada |
 |
OptiNose
OPTN
|
312 M | - | - | $ 1.08 B | USA |
 |
PLx Pharma
PLXP
|
73.8 M | - | -27.8 % | $ 2.56 M | USA |
 |
cbdMD
YCBD
|
7.85 M | $ 1.25 | 4.17 % | $ 5.39 M | USA |
 |
SCYNEXIS
SCYX
|
91.7 M | $ 0.64 | -0.56 % | $ 30.6 M | USA |
 |
Tricida
TCDA
|
506 M | - | - | $ 3.25 M | USA |
 |
Tilray
TLRY
|
1.96 B | $ 11.11 | -8.56 % | $ 6.87 B | Canada |
 |
TherapeuticsMD
TXMD
|
33.6 M | $ 1.73 | -1.14 % | $ 18.1 M | USA |
 |
Zomedica Corp.
ZOM
|
137 M | - | -0.21 % | $ 98 M | USA |
 |
Viatris
VTRS
|
41.3 B | $ 11.69 | 0.34 % | $ 14.2 B | USA |